Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4028-33.

3.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O.

J Natl Cancer Inst. 1996 Jul 17;88(14):994-9.

PMID:
8667431
4.

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH.

J Clin Invest. 1999 Nov;104(10):1441-7.

5.

The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.

Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC.

Cancer Res. 2001 Feb 15;61(4):1469-76.

6.

Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice.

Zhang ZJ, Saito T, Kimura Y, Sugimoto C, Ohtsubo T, Saito H.

Brain Res. 2000 Jan 3;852(1):116-26.

PMID:
10661503
7.
8.
9.

Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.

Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, Schinkel AH.

Mol Pharmacol. 2000 Jan;57(1):188-97. Erratum in: Mol Pharmacol 2000 Jun;57(6):1271.

PMID:
10617694
10.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.

Mol Cancer Ther. 2008 Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250.

11.

Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.

van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2010 Dec 15;127(12):2959-64. doi: 10.1002/ijc.25279.

12.

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH.

J Clin Invest. 1997 Nov 15;100(10):2430-6.

13.

Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport.

Sadiq MW, Uchida Y, Hoshi Y, Tachikawa M, Terasaki T, Hammarlund-Udenaes M.

PLoS One. 2015 May 1;10(5):e0118638. doi: 10.1371/journal.pone.0118638. eCollection 2015.

14.
15.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5.

16.

Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice.

Xie Y, Liu J, Liu Y, Klaassen CD, Waalkes MP.

Mol Cell Biochem. 2004 Jan;255(1-2):11-8.

PMID:
14971641
17.

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2013 Oct;76:9-16. doi: 10.1016/j.phrs.2013.06.009. Epub 2013 Jul 1.

PMID:
23827160
18.

Tissue distribution and chemical induction of multiple drug resistance genes in rats.

Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD.

Drug Metab Dispos. 2002 Jul;30(7):838-44.

PMID:
12065443
19.

Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.

Goralski KB, Hartmann G, Piquette-Miller M, Renton KW.

Br J Pharmacol. 2003 May;139(1):35-48.

20.

Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.

Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, Quiason CM, Yang L.

Mol Pharm. 2014 Nov 3;11(11):4199-207. doi: 10.1021/mp500435s. Epub 2014 Oct 3.

PMID:
25243894

Supplemental Content

Support Center